NasdaqGM:ALVOBiotechs
A Look at Alvotech (NasdaqGM:ALVO) Valuation Following FDA Setback and Revenue Guidance Cut
Alvotech (NasdaqGM:ALVO) stock stumbled after the company disclosed a setback with its AVT05 biosimilar, prompted by an FDA Complete Response Letter outlining manufacturing deficiencies and a significant reduction in its 2025 revenue guidance.
See our latest analysis for Alvotech.
After a long stretch of promising clinical milestones and regulatory approvals in Europe, Alvotech’s share price has now tumbled sharply, down nearly 39% in the past month, following the steep cut to its 2025...